Integra LifeSciences
IART | NASDAQ
$13.98
-$0.42 (-2.92%)
At close: Nov 16, 2026, 4:00 PM ET
$13.98
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Integra LifeSciences Company Profile
Company profile explainedCompany Profile
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Stuart Essig | CEO, President & Chairman |
| Lea Daniels Knight | Executive Vice President & Chief Financial Officer |
| Michael D. Hutchinson | Executive Vice President, Chief Legal Officer & Secretary |
| Teshtar Elavia | Corporate VP & Chief Technology Officer |
| Christopher Ward | Senior Director of Investor Relations |
| Harvinder Singh | Executive Vice President & President of International Business |
| Jeffrey Mosebrook | Senior Vice President of Finance & Principal Accounting Officer |
| Laurene Isip | Vice President of Global Corporate Communications & Public Relations |
| Michael J. McBreen | Executive VP & Chief Commercial Officer |
| Robert T. Davis Jr. | Executive Vice President of Tissue Reconstruction and Distributed Technologies |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 10-Q | Quarterly Report |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 13, 2026 | 3 | Filing |
| Oct 09, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 3 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Integra LifeSciences
| Country | United States |
| IPO Date | Aug 16, 1995 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 4,427 |
| CEO | Stuart Essig |
Contact Details
1100 Campus Road Princeton,
New Jersey 08540 United States
Stock Details
| Ticker Symbol | IART |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000917520 |
| CUSIP Number | 457985208 |
| ISIN Number | US4579852082 |
| SIC Code | 3841 |
Recent News
- 6 days ago / seekingalpha.comIntegra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
- 26 days ago / seekingalpha.comIntegra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript
- 27 days ago / fool.comIntegra: 3 Key Takeaways for Long-Term Investors
- 27 days ago / marketbeat.comWhat Integra LifeSciences (IART) Said on Its Q3 Earnings Call
- 27 days ago / zacks.comIntegra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- 27 days ago / zacks.comIntegra LifeSciences (IART) Surpasses Q3 Earnings Estimates
- 27 days ago / globenewswire.comIntegra LifeSciences Reports Third Quarter 2026 Financial Results
- 28 days ago / globenewswire.comIntegra Announces Completion of Refinancing Transactions
- 1 month ago / globenewswire.comIntegra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
- 1 month ago / gurufocus.comA Look at Integra Lifesciences Holdings Corp (IART) After 3.1% Gain -- GF Value $20.47 vs Price $13.41
Add to Watchlist
Select watchlists to add or remove IART